Table 2.
Extracellular vesicles investigated in clinical studies
|
Research title
|
Interventions
|
Status
|
| Treatment of Patients with Bone Tissue Defects Using Mesenchymal Stem Cells Enriched by Extracellular Vesicles | MSCs enriched by extracellular vesicles | Not yet recruiting |
| Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS | Bone Marrow MSC Derived Extracellular | Not yet recruiting |
| Efficacy of Platelet- and Extracellular Vesicle-rich Plasma in Chronic Postsurgical Temporal Bone Inflammations | Plateletand extracellular vesicle-rich plasma | Completed |
| Use of Autologous Plasma Rich in Platelets and Extracellular Vesicles in the Surgical Treatment of Chronic Middle Ear Infections | Plateletand EVs-rich plasma | Recruiting |
| Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS | ExoFlo | Completed |
| Safety of Mesenchymal Stem Cell Extracellular Vesicles (BMMSC-EVs) for the Treatment of Burn Wounds | Drug: AGLE-102 (BMMSC-EVs) | Not yet recruiting |
| Treatment of Non-ischemic Cardiomyopathies by Intravenous ExtracellularVesicles of CardiovascularProgenitor Cells | Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells | Not yet recruiting |
| Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial | Drug: ExoFlo. Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles | Not yet recruiting |
| A Safety Study of IV Stem Cellderived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD | UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline | Terminated |
| ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post COVID-19 Syndrome | Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles | Not yet recruiting |
| Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis | ExoFlo. Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles | Recruiting |
| Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease | ExoFlo. Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles | Recruiting |
| Bone Marrow Mesenchymal Stem Cell Derived EVs for COVID-19 Moderate-to-Severe ARDS: A Phase III Clinical Trial | EXOFLO. Bone Marrow Mesenchymal Stem Cell Derived EVs | Recruiting |
| Pilot Study of Human Adipose Tissue Derived Exosomes Promoting Wound Healing | Adipose tissue derived exosomes | Not yet recruiting |
| Exosome Effect on Prevention of Hairloss | Placental Mesenchymal Stem Cells-derived Exosome | Recruiting |
| Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients | Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment | Not yet recruiting |
| Safety of Injection of Placental Mesenchymal Stem Cell Derived Exosomes for Treatment of Resistant Perianal Fistula in Crohn's Patients | Placenal MSC derived exosomes | Active, not recruiting |
| Safety and Efficacy of Injection of Human Placenta Mesenchymal Stem Cells Derived Exosomes for Treatment of Complex Anal Fistula | Placenta MSCs derived exosomes | Recruiting |
| Safety and Tolerability Study of MSC Exosome Ointment | Exosome ointment | Completed |
| The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants | Exosomes derived from MSCs | Not yet recruiting |
ARDS: Acute Respiratory Distress Syndrome; MSC: Mesenchymal stromal cells; COVID-19: Coronavirus disease 2019; EVs: Extracellular vesicles.